-
Mashup Score: 4Favorable effect of CD26/DPP-4 inhibitors on postoperative outcomes after lung transplantation: A propensity-weighted analysis - 3 month(s) ago
We have shown the efficacy of CD26/dipeptidyl peptidase 4 (CD26/DPP-4) inhibitors, antidiabetic agents, in allograft protection after experimental lung transplantation (LTx). We aimed to elucidate whether CD26/DPP-4 inhibitors effectively improve postoperative outcomes after clinical LTx.
Source: www.jhltonline.orgCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 9Short airway telomeres are associated with primary graft dysfunction and chronic lung allograft dysfunction - 4 month(s) ago
Primary graft dysfunction (PGD) is a major risk factor for chronic lung allograft dysfunction (CLAD) following lung transplantation, but the mechanisms linking these pathologies are poorly understood. We hypothesized that the replicative stress induced by PGD would lead to erosion of telomeres, and that this telomere dysfunction could potentiate CLAD.In a longitudinal cohort of 72 lung transplant recipients with >6 years median follow-up time, we assessed tissue telomere length, PGD grade, and freedom from CLAD.
Source: www.jhltonline.orgCategories: General Medicine News, Cardiology News and JournTweet-
Telomeres may impact #LungTx survival. Does primary graft dysfunction affect airway telomeres? New data suggest yes. @jrgreenland @jsinger0 @shaysmd 🔗 https://t.co/HpAXFpLUfF
-
-
Mashup Score: 0Clinical outcomes following cessation of parenteral immunoglobulin therapy following lung transplantation - 5 month(s) ago
Broad use of parenteral immunoglobulin (IgG) therapy in lung transplant (LTx) patients occurs without robust clinical evidence or guidelines. Main indications include secondary hypogammaglobulinemia, antibody-mediated rejection (AMR), and treatment or prevention of graft rejection where the use of conventional immunosuppressive therapies is contraindicated. As part of routine auditing of IgG use in our LTx service, we assessed for adverse clinical outcomes related to IgG therapy cessation between November 2017 and February 2022.
Source: www.jhltonline.orgCategories: General Medicine News, Cardiology News and JournTweet-
Presenting real-world clinical data to help guide physician decision making when prescribing and ceasing immunoglobulin therapy following #LungTx @kloeVa 🔗 https://t.co/tYsRdwJRrx
-
-
Mashup Score: 9
Predicting risk of waitlist mortality and subsequent classification of lung transplant candidates has been difficult due to inter-relatedness of risk factors, differential risk across populations, and changes in relationships over time. We developed a clinically intuitive indexing system to simplify mortality risk assessment.
Source: www.jhltonline.orgCategories: General Medicine News, Cardiology News and JournTweet-
Is there a better way to capture waitlist mortality risk for #LungTx patients? Using clinically-interpretable dimensions leads to improved phenotyping and better understanding of mortality risk. @CarliLehrMDPhD @MValapour @DaltonJarrod 🔗https://t.co/5KCDX3qaRC
-
-
Mashup Score: 0Clinical relevance of cell-free DNA quantification and qualification during the first month after lung transplantation - 6 month(s) ago
BackgroundMany studies have reported the relevance of donor-derived cfDNA (dd-cfDNA) after lung transplantation (LTx) to diagnose and monitor acute rejection (AR) or chronic rejection or infection (INF). However, the analysis of cfDNA fragment size has not been studied. The aim of this study was to determine the clinical relevance of dd-cfDNA and cfDNA size profiles in events (AR and INF) during the first month after LTx.MethodsThis prospective, single-center study includes 62 LTx recipients at the Marseille Nord Hospital, France. Total cfDNA quantification was performed by fluorimetry and digital PCR, dd-cfDNA by NGS (AlloSeq cfDNA-CareDX®), and the size profile by BIABooster (Adelis®). A bronchoalveolar lavage and transbronchial biopsies at D30 established the following groups: not-injured and injured graft (AR, INF, or AR+INF).ResultsQuantification of total cfDNA was not correlated with the patient’s status at D30. The percentage of dd-cfDNA was significantly higher for injured graf
Source: www.frontiersin.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
2⃣ Federica Pezzuto presents a study from @FrontImmunol by Pascal Pedini et al on the clinical relevance of #ddcfDNA and #cfDNA in evaluating patients after #LungTx. 🫁▶️ https://t.co/cacZ2mNwWp #ISHLT #ISHLTJournalWatch #ISHLTEarlyCareer https://t.co/8tHGSOorNC
-
-
Mashup Score: 8JHLT: The Podcast: Episode 35: October 2023 - 7 month(s) ago
The JHLT Digital Media Editors explore two manuscripts from the October issue of The Journal of Heart and Lung Transplantation—the first on lung transplantation in patients with stacked risks, and the second on bacterial pathogens found at driveline exit sites in patients with ventricular assist devices. Digital Media Editor Marty Tam, MD, assistant professor in the division of cardiovascular medicine at the University of Michigan, hosts this episode. First, hear from senior author Edward Cantu, MD, MSCE, on his team’s study “.” Lung transplant centers are increasingly evaluating patients with multiple risk factors for adverse post-transplant outcomes, yet there is little data of the effects of these risks as they stack. The authors of the study used the UNOS registry data linked to the National Inpatient Sample (NIS) to create a national encounter-level sample of healthcare data in the United States, then applied a probabilistic matching algorithm using 7 variables and determined
Source: thejhlt.libsyn.comCategories: Cardiologists, Latest HeadlinesTweet-
RT @TheJHLT: 🚨October #JHLTThePodcast! 🔗https://t.co/vW3QyOtRit We talk with @_EdCantu_ @PennMedicine on stacked risks in #LungTx candidate…
-
RT @TheJHLT: 🚨October #JHLTThePodcast! 🔗https://t.co/vW3QyOtRit We talk with @_EdCantu_ @PennMedicine on stacked risks in #LungTx candidate…
-
🚨October #JHLTThePodcast! 🔗https://t.co/vW3QyOtRit We talk with @_EdCantu_ @PennMedicine on stacked risks in #LungTx candidates, and discuss bacterial pathogens in driveline infections in #VAD patients from University Hospital, Bern. https://t.co/xn2ccyc5qt
-
-
Mashup Score: 3ISHLT: The International Society for Heart & Lung Transplantation - Research Grants - 8 month(s) ago
Accept Cookies & Privacy Policy? This website uses cookies to ensure the best possible web experience. By continuing and using the site, you consent to the use of cookies. If you wish to disable them or to learn more about how we use cookies, please view our Cookies Policy. …
Source: ishlt.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Are you or a colleague doing cutting-edge work on #biomarkers, #BOS, or #ddcfDNA? Don't miss the opportunity to apply for NEW 2023 #ISHLTResearchGrants. 📅You have until the end of Sep to apply! 🔗https://t.co/Q3zlmjTWpf #ISHLT #HeartTx #LungTx https://t.co/fpvF8KEYE7
-
-
Mashup Score: 1JHLT: The Podcast: Episode 33: August 2023 - 8 month(s) ago
The JHLT Digital Media Editors explore two manuscripts from the August issue of The Journal of Heart and Lung Transplantation—the first on immunosuppression in pediatric heart transplantation, and the second TA-NRP in DCD lung transplantation. Digital Media Editor Van-Khue Ton, MD, heart failure and transplant cardiologist at Massachusetts General Hospital, hosts this episode. First, hear from senior author Steven C. Greenway, MSc, MD, on his team’s study “.” Dr. Greenway shares his journey from enzyme biochemistry in mollusks, snails, and frogs to pediatric cardiology, then outlines the results of the paper. The study queried the Pediatric Heart Transplant Society’s registry to determine the efficacy and safety of monotherapy immunosuppression. The results showed better graft survival and less coronary allograft vasculopathy in the monotherapy group, even after adjusted for age at transplant, sex, neonatal transplant, infection, PTLD, and etiology of cardiomyopathy. Dr. Greenway a
Source: thejhlt.libsyn.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Listen to the August #JHLTThePodcast for great discussions on #immunosuppression in peds #HeartTx and TA-NRP on early outcomes in #DCD #LungTx from Steven C. Greenway and @JadMalasMD. Check the 🧵thread below for details on the studies, and listen at https://t.co/pVodmrbHMV https://t.co/N7EiMw2ZzB
-
-
Mashup Score: 0Tocilizumab for antibody-mediated rejection treatment in lung transplantation - PubMed - 8 month(s) ago
Tocilizumab (TCZ), an IL-6 inhibitor, has shown promise in the treatment of donor-specific antibodies (DSA) and chronic antibody-mediated rejection (AMR) in renal transplant recipients. However, its use in lung transplantation has not been described. This retrospective case-control study compared AM …
Source: pubmed.ncbi.nlm.nih.govCategories: Cardiology News and Journals, Latest HeadlinesTweet-
1⃣ @KrystaWalter12 presents a study from June @TheJHLT on #Tocilizumab for #AMR Treatment in #LungTx, by first author S.E. January. 🫁▶️https://t.co/5ARZOgHRDC #ISHLTJournalWatch #ISHLTEarlyCareer https://t.co/vgnKINLS5H
-
-
Mashup Score: 1First use of imlifidase desensitization in a highly sensitized lung transplant candidate: a case report - PubMed - 8 month(s) ago
Lung transplant candidates who are highly sensitized against human leucocyte antigen present an ongoing challenge with regards to finding immunologically acceptable donors. Desensitization strategies aimed at reducing preformed donor-specific antibodies have a number of limitations. Imlifidase, an I …
Source: pubmed.ncbi.nlm.nih.govCategories: Cardiology News and Journals, Latest HeadlinesTweet-
2⃣ Ashley Postell @MayoClinic shares a case report on first use of #Imlifidase desensitization in a highly #sensitized #LungTx Candidate, by first author @drAntoineRoux. 🫁▶️https://t.co/nTmgTckhIS #ISHLTJournalWatch #ISHLTEarlyCareer https://t.co/RWQ0EaupeI
-
CD26/DPP-4 inhibitors, typically used to treat DM, had a favorable effect on postoperative prognosis in #LungTx recipients through a propensity-weighted analysis. Should we consider using CD26/DPP-4 inhibitors regardless of DM status? 🔗 https://t.co/xTUAJQrKom